RxDoctor Payments Data

Tracy Hwangpo

Allergy & Immunology · Birmingham, ALNPI 1841451101

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by CSL Behring at 54.6% of the total. Reporting peaked in 2024 at $2,591 and has fallen 76.3% since, to $614 in 2025. That places this record below the midpoint for allergy & immunology clinicians in AL, where the typical reported total is $8,006.

$5,074in general payments, 2019–2025

Across 47 payments — averaging $107.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$3K
  • Blueprint Medicines Corporation$585
  • AstraZeneca$564
  • Takeda Pharmaceuticals U.S.A., Inc.$414
  • Amgen$333
  • Genentech USA, Inc.$125
  • plus $284 from 5 others

What the payments were for

  • Consulting fees$2,53550%
  • Food & beverage$2,53950%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,074 in reported general payments places this provider in the 45th percentile of 30 allergy & immunology providers in Alabama.

See all allergy & immunology providers in Alabama

Medicare billing

Part B allowed, 2024
$20,013
Medicare patients
149
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-50160$1,178,088
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5060$416,506
Gamunex-CImmune Globul G/Gly/Iga Avg 4648$198,050
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5049$151,916
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5017$114,128
Epinephrine46$13,644
Azithromycin106$2,804
Fluticasone Propionate21$687
Ipratropium Bromide13$424
Levocetirizine Dihydrochloride24$319
Doxycycline Monohydrate15$311
Lidocaine-PrilocaineLidocaine/Prilocaine27$291
Sodium Chloride0.9 % Sodium Chloride27$198
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$57
Diphenhydramine Hcl17$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra, Privigen$2,769$1,292,216177 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$414$416,50660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 30 allergy & immunology providers in Alabama.

Other allergy & immunology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →